Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab

Brett A. Schroeder*, Karan Kohli, Ryan B. O’Malley, Theresa S. Kim, Robin L. Jones, Robert H. Pierce, Seth M. Pollack

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase inhibitors (TKIs), including imatinib, sunitinib, and regorafenib, all of which are FDA approved. However, TKIs are not always well-tolerated, and the refractory disease continues to be a problem. For these reasons, alternative treatments are needed. In this report, we discuss a patient with metastatic wild-type (WT) GIST refractory to multiple TKIs, but with a durable clinical response to the anti-programmed cell death protein 1 (PD-1) antibody, nivolumab. This report suggests that continued research evaluating checkpoint inhibitors in GIST is warranted.

Original languageEnglish (US)
Article number1710064
JournalOncoImmunology
Volume9
Issue number1
DOIs
StatePublished - Jan 1 2020
Externally publishedYes

Keywords

  • GIST
  • Imatinib
  • Metastatic
  • Nivolumab
  • PD-1
  • PD-L1
  • Refractory
  • Sarcoma
  • Wild-Type

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Fingerprint Dive into the research topics of 'Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab'. Together they form a unique fingerprint.

Cite this